|
|
Gene Symbol |
ADA |
|
Aliases |
- |
|
Entrez Gene ID |
|
|
Gene Name |
Adenosine deaminase |
|
Chromosomal Location |
20q13.12 |
|
HGNC ID |
|
|
Summary |
This gene encodes an enzyme that catalyzes the hydrolysis of adenosine to inosine in the purine catabolic pathway. Various mutations have been described for this gene and have been linked to human diseases related to impaired immune function such as severe combined immunodeficiency disease (SCID) which is the result of a deficiency in the ADA enzyme. In ADA-deficient individuals there is a marked depletion of T, B, and NK lymphocytes, and consequently, a lack of both humoral and cellular immunity. Conversely, elevated levels of this enzyme are associated with congenital hemolytic anemia. [provided by RefSeq, Sep 2019]
|
|
RefSeq DNA |
|
|
RefSeq mRNA |
|
|
e!Ensembl
|
Gene Ontology (GO)
GO ID |
Ontology |
Function |
Evidence |
Reference |
GO:0001666 |
Biological process |
Response to hypoxia |
IDA |
16670267 |
GO:0006154 |
Biological process |
Adenosine catabolic process |
IBA |
21873635 |
GO:0006154 |
Biological process |
Adenosine catabolic process |
IDA |
8894685, 16670267 |
GO:0032261 |
Biological process |
Purine nucleotide salvage |
IMP |
9361033 |
GO:0033632 |
Biological process |
Regulation of cell-cell adhesion mediated by integrin |
IDA |
11772392 |
GO:0042110 |
Biological process |
T cell activation |
IBA |
21873635 |
GO:0042110 |
Biological process |
T cell activation |
IDA |
7594462 |
GO:0043103 |
Biological process |
Hypoxanthine salvage |
IBA |
21873635 |
GO:0046103 |
Biological process |
Inosine biosynthetic process |
IBA |
21873635 |
GO:0046103 |
Biological process |
Inosine biosynthetic process |
IDA |
8894685 |
GO:0060169 |
Biological process |
Negative regulation of adenosine receptor signaling pathway |
IBA |
21873635 |
GO:0060169 |
Biological process |
Negative regulation of adenosine receptor signaling pathway |
IDA |
16670267 |
GO:0005764 |
Cellular component |
Lysosome |
IDA |
8452534 |
GO:0005829 |
Cellular component |
Cytosol |
IBA |
21873635 |
GO:0009897 |
Cellular component |
External side of plasma membrane |
IBA |
21873635 |
GO:0009897 |
Cellular component |
External side of plasma membrane |
IDA |
7759315, 16670267 |
GO:0009986 |
Cellular component |
Cell surface |
IDA |
7594462, 11772392 |
GO:0016020 |
Cellular component |
Membrane |
IDA |
11999881 |
GO:0004000 |
Molecular function |
Adenosine deaminase activity |
EXP |
3182793 |
GO:0004000 |
Molecular function |
Adenosine deaminase activity |
IBA |
21873635 |
GO:0004000 |
Molecular function |
Adenosine deaminase activity |
IDA |
3182793, 8452534, 8894685, 9361033, 11999881, 16670267 |
GO:0005515 |
Molecular function |
Protein binding |
IPI |
7594462, 8101391, 14684150 |
GO:0008270 |
Molecular function |
Zinc ion binding |
IMP |
7599635 |
|
Protein Information |
|
Protein Name |
Adenosine deaminase, adenosine aminohydrolase |
|
Function |
Catalyzes the hydrolytic deamination of adenosine and 2-deoxyadenosine (PubMed:8452534, PubMed:16670267). Plays an important role in purine metabolism and in adenosine homeostasis. Modulates signaling by extracellular adenosine, and so contributes indirectly to cellular signaling events. Acts as a positive regulator of T-cell coactivation, by binding DPP4 (PubMed:20959412). Its interaction with DPP4 regulates lymphocyte-epithelial cell adhesion (PubMed:11772392). Enhances dendritic cell immunogenicity by affecting dendritic cell costimulatory molecule expression and cytokines and chemokines secretion (By similarity). Enhances CD4+ T-cell differentiation and proliferation (PubMed:20959412). Acts as a positive modulator of adenosine receptors ADORA1 and ADORA2A, by enhancing their ligand affinity via conformational change (PubMed:23193172). Stimulates plasminogen activation (PubMed:15016824). Plays a role in male fertility (PubMed:21919946, PubMed:26166670). Plays a protective role in early postimplantation embryonic development (By similarity). |
|
|
|
|
|
UniProt |
|
|
PDB |
|
|
Pfam |
Pfam Accession |
Pfam ID |
PF00962 |
A_deaminase |
|
|
|
|
Interactions |
| |
STRING |
MINT |
IntAct |
ENSP00000458832 |
|
P16050 |
|
| |
View interactions
|
|
| |
Associated Diseases
Disease group | Disease Name | References |
Cardiovascular Diseases |
Hyperemia |
|
Endocrine System Diseases |
PCOS |
|
Immune System Diseases |
SCID |
2166947, 8614422, 980079, 1974554, 46025, 11313286, 11160213, 498598, 26255240, 14499267, 20544538, 8401541, 3839802, 1284479, 3007108, 8031011, 3182793, 9758612, 24033266, 2773932, 1346349, 27129325, 3475710, 9414266, 28492532, 8673127, 1680289, 26376800, 23260757, 2783588, 3, 7599635, 8227344, 6208479, 10200056, 9361033, 8299233 |
ADA Deficiency |
8299233, 9361033, 6208479, 8227344, 3182793, 7599635, 3839802, 2166947, 1284479, 10200056, 2783588, 9225964, 8051429 |
Neoplasms |
Pancreatic Ductal Adenocarcinoma |
|
Lung Cancer |
|
Nervous System Diseases |
Spinal Cord Diseases |
|
Psychiatric/Brain disorders |
Autistic Disorder |
|
|
References |
|
|
|
PubMed ID |
Associated gene/s |
Associated condition |
Genetic Mutation |
Diagnostic Criteria |
Association with PCOS |
Ethnicity |
Conclusion |
|
ADA2 |
PCOS |
G22A, A4223C |
|
Direct
|
200 PCOS control patients and 200 healthy women |
The results of the present study showed that serum total adenosine deaminase catalytic activity (tADA) as well as ADA1, and ADA2 enzyme activities were significantly reduced in PCOS compared to control healthy women. |
|
|
|
|